Nederlands tijdschrift voor geneeskunde · 1994
[Autologous bone marrow transplantation in the treatment of children with neuroblastoma; 30 patients in 10 years].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Kraker J, Boon F, van Leeuwen E F, Voûte P A
Аннотация
OBJECTIVE: To evaluate the role of high dose chemotherapy and autologous bone marrow transplantation (ABMT) in children with metastasized neuroblastoma (stage IV) in partial or complete remission.
DESIGN: Retrospective analysis.
SETTING: The former Emma Child Hospital and the Academic Medical Center, Amsterdam.
METHOD: In the period January 1980 to May 1991, ABMT was used in 30 children (mean age 3 years) with a neuroblastoma stage IV treated with chemotherapy. Occurrence of fever, infections, haemorrhagic diathesis, mucositis, ileus and the duration of hospital stay were measured as indications of illness. The mean weight loss and the duration of aplasia were also measured.
RESULTS: Eight of 30 patients stayed alive until June 1993. Three patients died within 1 month after start of treatment. The median survival of the other 19 patients was 15 months. The mean weight loss was 7.6% and the period of aplasia had a mean duration of 18-20 days. Two-year disease free survival was 26.6% with a median follow-up of 118.5 months (29-150).
DESIGN: Retrospective analysis.
SETTING: The former Emma Child Hospital and the Academic Medical Center, Amsterdam.
METHOD: In the period January 1980 to May 1991, ABMT was used in 30 children (mean age 3 years) with a neuroblastoma stage IV treated with chemotherapy. Occurrence of fever, infections, haemorrhagic diathesis, mucositis, ileus and the duration of hospital stay were measured as indications of illness. The mean weight loss and the duration of aplasia were also measured.
RESULTS: Eight of 30 patients stayed alive until June 1993. Three patients died within 1 month after start of treatment. The median survival of the other 19 patients was 15 months. The mean weight loss was 7.6% and the period of aplasia had a mean duration of 18-20 days. Two-year disease free survival was 26.6% with a median follow-up of 118.5 months (29-150).